Market Trends of Cell Therapy Industry
The Allogeneic Segment is Expected to Account for a Significant Share in the Market During the Forecast Period
Allogeneic cell therapies use a single source of cells to treat many patients. A master cell bank (MCB) is created by collecting cells from a donor sample. The MCB is then used as a source to generate cell populations processed by the specific therapy's requirements. Consequently, the growing interest among physicians in the therapeutic application of allogeneic therapies and heightened awareness regarding the use of cord cells and tissues in various therapeutic fields are significant contributors to this growth. Allogeneic cells offer advantages as they generate immune stem cells capable of targeting and eliminating cancer cells that persist even after intensive treatments with cytotoxic drugs. This phenomenon, known as the graft-versus-cancer effect, plays a crucial role in preventing or managing cancer recurrence.
Factors such as the rising prevalence of chronic diseases, rising adoption of regenerative medicine, and increased clinical trials for the development of allogeneic cell therapies are expected to propel the allogeneic cell therapy market growth during the study period. For instance, in June 2024, Allogene Therapeutics Inc. and Foresight Diagnostics introduced the launch of the pivotal Phase 2 ALPHA3 trial. This trial will evaluate the use of the allogeneic cell therapy product cemacabtagene ansegedleucel (cema-cel) in the first-line (1L) treatment regimen for newly diagnosed large B-cell lymphoma (LBCL) patients who are at high risk of relapse following standard first-line treatment and require additional therapy. Hence, such initiatives are likely to increase the demand for allogenic therapies and drive the growth of the allogeneic cell therapy market during the forecast period.
Additionally, in May 2024, Astellas Pharma Inc. and Poseida Therapeutics Inc. formed a research collaboration and licensing agreement to develop innovative allogeneic cell therapies for oncology. The companies intend to integrate Poseida's proprietary allogeneic CAR-T platform with Xyphos' ACCELTM technology to create a CAR-T construct developed by Poseida, which will serve as the foundation for two convertible CAR product candidates aimed at treating solid tumors. Thus, such collaborations by market players to develop allogeneic cell therapies are anticipated to drive the growth of the allogeneic cell therapy market.
Thus, with the increasing number of research studies on allogeneic cell therapy for cancer and its related benefits, the studied segment is expected to experience consistent growth during the forecast period.
North America is Expected to Witness Growth During the Forecast Period
North America is estimated to hold a significant share of the global cell therapy market owing to key industry players and research institutes supporting research activities in the region. The market's significant growth in the region can be attributed to several factors, including the rising prevalence of chronic conditions, the growing adoption of regenerative medicine, and an increase in clinical studies focused on the development of cellular therapies.
The growing burden of chronic diseases such as cancer raises the need for cell therapy in the United States. For instance, in January 2024, as per the American Cancer Society 2024 update, the estimated number of new cancer cases in the United States is anticipated to be 2.0 million in 2024, which is an increase from the previous year's estimated cancer cases of 1.9 million. Thus, the rising cancer cases are likely to fuel the demand for effective cell therapy and contribute to the growth of the U.S. cell therapy market.
Rising investments from market players for developing and expanding cell-based therapies development in the United States are expected to drive the market in North America. For instance, in October 2023, Bayer AG invested USD 250 million in a new cell therapy manufacturing facility in the United States to support the production of materials needed for clinical trials and the potential commercial launch of BlueRock Therapeutics' bemdaneprocel (BRT-DA01), an investigational cell therapy under evaluation for the treatment of Parkinson's Disease. Thus, such investments by market players in developing novel therapies in this area are driving the growth of the U.S. cell therapy market during the forecast period.
Additionally, the enhanced outcomes of cell therapy products for cancer treatment are expected to result in increased product development, which should promote the growth of this market. For instance, in March 2024, Bristol-Myers Squibb received the US FDA approval for a CD19-directed chimeric antigen receptor (CAR) T cell therapy, Breyanzi (lisocabtagene maraleucel), indicated in the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In addition, in January 2024, Kite, a Gilead company, received approval from the United States Food and Drug Administration for the change in the manufacturing process, which will lead to the reduction in the manufacturing time of CAR T-cell therapy Yescarta (axicabtagene ciloleucel) from 16 days to 14 days in the United States and the early release and delivery of Yescarta products, enabling healthcare professionals to provide better support to patients. Thus, rising product approvals in the region are anticipated to contribute to the market's growth.
Therefore, rising investments and research initiatives by the key market players and positive results of cell therapies are expected to drive the market's growth in North America, reflecting a positive U.S. stem cell therapy market outlook.
